India remembers Nehru on his 127 birth anniversary

New Delhi, May 6: The death toll due to COVID-19 rose to 1,694 and the number of cases climbed to 49,391 in the country on Wednesday, registering an increase of 126 deaths and 2,958 cases in the last 24 hours, the Union Health Ministry said.

The number of active COVID-19 cases is 33,514. A total of 13,160 people have recovered and one patient has migrated, it said.

"Thus, around 28.71 per cent patients have recovered so far," a senior health ministry official said.

The total number of cases include 111 foreign nationals.

A total of 111 deaths were reported since Tuesday evening, of which 49 fatalities were reported from Gujarat, 34 from Maharashtra, 12 from Rajasthan, seven from West Bengal, three from Uttar Pradesh, two each from Punjab and Tamil Nadu and one each from Karnataka and Himachal Pradesh, the ministry said.

Of the 1,694 fatalities, Maharashtra tops the tally with 617 fatalities. Gujarat comes second with 368 deaths, followed by Madhya Pradesh at 176, West Bengal at 140, Rajasthan at 89, Delhi at 64, Uttar Pradesh at 56 and Andhra Pradesh at 36.

The death toll reached 33 in Tamil Nadu, 29 in Telengana, while Karnataka has reported 29 fatalities.

Punjab has registered 25 COVID-19 deaths, Jammu and Kashmir eight, Haryana six and Kerala and Bihar four deaths each.

Jharkhand has recorded three COVID-19 fatalities.

Meghalaya, Chandigarh, Himachal Pradesh, Odisha, Assam and Uttarakhand have reported one fatality each, according to the ministry data.

According to the health ministry data updated in the morning, the highest number of confirmed cases in the country are from Maharashtra at 15, 525, followed by Gujarat at 6,245, Delhi at 5,104, Tamil Nadu at 4,058, Rajasthan at 3,158, Madhya Pradesh at 3,049 and Uttar Pradesh at 2,880.

The number of COVID-19 cases has gone up to 1,717 in Andhra Pradesh and 1,451 in Punjab.

It has risen to 1,344 in West Bengal, 1,096 in Telengana, 741 in Jammu and Kashmir, 671 in Karnataka, 548 in Haryana and 536 in Bihar.

Kerala has reported 502 coronavirus cases so far, while Odisha has 175 cases. A total of 125 people have been infected with the virus in Jharkhand and 111 in Chandigarh.

Uttarakhand has reported 61 cases, Chhattisgarh 59 cases, Assam 43, Himachal Pradesh 42 and Ladakh 41.

Thirty-three COVID-19 cases have been reported from the Andaman and Nicobar Islands.

Tripura has registered 43 cases, Meghalaya has reported 12 and Puducherry nine, while Goa has seven COVID-19 cases.

Manipur has two cases. Mizoram, Arunachal Pradesh and Dadar and Nagar Haveli have reported a case each.

"Our figures are being reconciled with the ICMR," the ministry said on its website.

State-wise distribution is subject to further verification and reconciliation, it said.

New Delhi, Feb 13: Tibetan spiritual leader the Dalai Lama has congratulated AAP supremo Arvind Kejriwal for his party's stupendous victory in the Delhi Assembly polls, saying the people of the national capital will continue to benefit from his leadership.

Responding to the Dalai Lama's statement, Kejriwal in a tweet on Wednesday said, "Am humbled by the kind words and blessings from His Holiness The Dalai Lama. Thank you very much @DalaiLama."

Referring to the Happiness Curriculum for government schools in Delhi, the Dalai Lama said he has a deep admiration for the efforts the AAP government has made towards "shaping better, happier human beings with improved values".

"These measures will have a positive impact on children's overall education, as well as helping the poor to fulfil their dreams of improving their lives," he said.

He also lauded the AAP government's initiative to incorporate aspects of inner mental development into the school curriculum.

"Through such initiatives, you are showing a path to the rest of India," the Dalai Lama added.

In a near-repeat performance of 2015, the Aam Aadmi Party on Tuesday retained power with a stunning victory, winning 62 of the 70 assembly seats and leaving the BJP with just eight seats.

Hyderabad, Jun 30: Hyderabad-based Bharat Biotech announced that it has successfully developed Covaxin, India's first vaccine candidate for Covid-19, in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).

The Drug Controller General of India - CDSCO, Ministry of Health & Family Welfare granted permission to initiate Phase I & II Human clinical trials after the company submitted results generated from preclinical studies, demonstrating safety and immune response. Human clinical trials are scheduled to start across India in July 2020.

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech.

The indigenous, inactivated vaccine developed and manufactured in the company's Bio-Safety Level 3 (BSL-3) High Containment facility located in Genome Valley, Hyderabad.

Announcing the vaccine development milestone, Dr Krishna Ella, Chairman and Managing Director said: "We are proud to announce COVAXIN, India's first indigenous vaccine against COVID-19. The collaboration with ICMR and NIV was instrumental in the development of this vaccine."

Dr Ella added, "The proactive support and guidance from CDSCO has enabled approvals to this project. Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform."
Expedited through national regulatory protocols, the company accelerated its objective in completing the comprehensive pre-clinical studies. Results from these studies have been promising and show extensive safety and effective immune responses.

Speaking about Bharat Biotech's prowess, Suchitra Ella, Joint Managing Director said, "Our ongoing research and expertise in forecasting epidemics has enabled us to successfully manufacture a vaccine for the H1N1 pandemic."
"Continuing our focus on creating the only BSL-3 containment facilities for manufacturing and testing in India, Bharat Biotech is committed to advancing vaccine development as a matter of national importance to demonstrate India's strength in handling future pandemics," she added.

Bharat Biotech's track record in developing vero cell culture platform technologies has been proven in several vaccines for Polio, Rabies, Rotavirus, Japanese Encephalitis, Chikungunya and Zika.